Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
暂无分享,去创建一个
O. Olopade | B. Weber | C. Berg | A. Nixon | J. Garber | M. Strawderman | L. Dawson | C. Isaacs | L. Pierce | L. Solin | A. Eisen | S. Narod | D. Gaffney | B. Haffty | R. Heimann | O. Olopade | I. Oliviotto | Barbara L. Weber | Ivo Oliviotto | C. Berg | Myla H. Strawderman
[1] D. B. Berman,et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.
[2] P Borgen,et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. , 1999, Journal of the National Cancer Institute.
[3] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[4] B. Hankey,et al. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. , 1983, Journal of the National Cancer Institute.
[5] R. Weichselbaum,et al. Significance of Family History in Breast Cancer Treated with Breast Conservation Therapy , 1996 .
[6] D J Schaid,et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.
[7] P. Roberson,et al. Dose to the contralateral breast due to primary breast irradiation. , 1985, International journal of radiation oncology, biology, physics.
[8] R. Arriagada,et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Klijn,et al. Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.
[10] M. Stratton. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.
[11] J. Klijn,et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.
[12] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[13] N. Risch,et al. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. , 1992, American journal of epidemiology.
[14] B. McCormick,et al. Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. , 1991, International journal of radiation oncology, biology, physics.
[15] M N Pollak,et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women , 1997, Cancer.
[16] F. Vicini,et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. , 1992, International journal of radiation oncology, biology, physics.
[17] S. Hellman,et al. The key and the lamppost. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] O. Olopade,et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.
[19] A. Coldman,et al. Radiation dose and second breast cancer. , 1985, British Journal of Cancer.
[20] C. Lewis,et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] J. Ranstam,et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Schnitt,et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. , 1988, International journal of radiation oncology, biology, physics.
[23] W. Willett,et al. Jewish religion and risk of breast cancer , 1996, The Lancet.
[24] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[25] M. King,et al. Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.
[26] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[27] W. Thompson,et al. The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.
[28] Yonghong Xiao,et al. Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.
[29] G. Eichele,et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.
[30] D. Schultz,et al. Family History Status as a Prognostic Factor for Breast Cancer Patients Treated with Conservative Surgery and Irradiation , 1995 .
[31] F. Vicini,et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. , 1991, International journal of radiation oncology, biology, physics.
[32] G J Kutcher,et al. Intensity-modulated tangential beam irradiation of the intact breast. , 1999, International journal of radiation oncology, biology, physics.
[33] M. Strawderman,et al. Conservative surgery and radiotherapy for early-stage breast cancer using a lung density correction: the University of Michigan experience. , 1997, International journal of radiation oncology, biology, physics.
[34] B Fisher,et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.
[35] M. Skolnick,et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Manola,et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Anthony J. Guidi,et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: Possible importance of family history. , 1995, The cancer journal from Scientific American.
[38] G M Lenoir,et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.
[39] D. Easton,et al. Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.
[40] B. Haffty,et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. , 1998, The cancer journal from Scientific American.
[41] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[42] A. Jacobsen,et al. Adjuvant radiotherapy and risk of contralateral breast cancer. , 1992, Journal of the National Cancer Institute.
[43] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[44] P Okunieff,et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. , 1995, The New England journal of medicine.
[45] B. Weber,et al. BRCA1 and BRCA2: from molecular genetics to clinical medicine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.